drugset / Trial / NCT01986270

Comparative Study of Oral Eletriptan (40mg and 80mg), Oral Sumatriptan (25mg and 50mg) and Placebo

NCT01986270

Phase 3 Completed 1141 enrolled Viatris Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this study was to compare the efficacy, toleration and safety of eletriptan 40mg and 80mg, with sumatriptan 25mg and 50mg, and placebo when given orally to subjects with an acute migraine.

Timeline

Start
1996-12
Primary completion
1998-01
Completion
1998-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Eletriptan Small molecule 40 mg Oral
Subject Eletriptan Small molecule 80 mg Oral
Subject Sumatriptan Unknown 25 mg Oral
Subject Sumatriptan Unknown 50 mg Oral

Indications